Improving the safety of intravenous iron treatments for patients with chronic kidney disease.

Improving the safety of intravenous iron treatments for patients with chronic kidney disease. Expert Opin Drug Saf. 2020 Nov 17;: Authors: Kassianides X, Hazara AM, Bhandari S Abstract Introduction: Iron deficiency anemia in chronic kidney disease (CKD) is common and has prognostic, financial and quality of life implications. Intravenous (IV) iron is a key intervention for optimal management, however ongoing safety concerns exist. Area covered: The potential side effects associated with IV iron use are addressed as we review the most recent studies. Hypersensitivity reactions and true anaphylaxis are indeed rare with a greater understanding of the nature of labile iron and 'Fishbane' reactions. Hypophosphatemia appears commoner with certain IV iron preparations, however its significance in CKD requires exploration. The long-standing questions regarding oxidative stress and the potential susceptibility to infections and worsening cardiovascular morbidity are discussed. Iron overload secondary to repeat IV iron infusions is plausible, however a number of guidelines limit and strictly guide prescription. Expert opinion: The past decade has improved our understanding of IV iron administration safety in patients with CKD. Third generation IV iron compounds have minimized hypersensitivity reactions while allowing high doses to be administered safely and rapidly in non-dialysisis-dependent CKD patients. However differences in safety profile...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research